Interleukin 6 [ Time Frame: Change from baseline to measurements taken daily for 7 days ] [ Designated as safety issue: No ]

5mls blood from arterial catheter, centrifuged at 1,500 for 10 minutes at 4 degrees C. The supernaturant will be collected and stored at -80 degrees C. The marker will be analyzed by an enzyme-linked immuno-assay.

Tumour necrosis factor alpha (TNF-alpha) [ Time Frame: Change from baseline to measurements taken daily for 7 days ] [ Designated as safety issue: No ]

5mls blood from arterial catheter, centrifuged at 1,500 for 10 minutes at 4 degrees C. The supernaturant will be collected and stored at -80 degrees C. The marker will be analyzed by an enzyme-linked immuno-assay.

Interleukin 10 [ Time Frame: Change from baseline to measurements taken daily for 7 days ] [ Designated as safety issue: No ]

5mls blood from arterial catheter, centrifuged at 1,500 for 10 minutes at 4 degrees C. The supernaturant will be collected and stored at -80 degrees C. The marker will be analyzed by an enzyme-linked immuno-assay.

These patients will not receive exercise early in their intensive care admission

Experimental: Exercise

Other: Exercise

The subjects will be given 2 x 30 minute sessions of exercise per day consisting of either passive, active, active assisted depending on level of sedation and stability of condition.

According to level of sedation and stability they may also perform sitting exercises

Detailed Description:

This study will investigate the effects of an early targeted rehabilitation program on inflammatory markers and muscle mass in patients with sepsis syndromes in intensive care.

The Primary Hypothesis is that an early targeted rehabilitation ICU patients with sepsis syndromes over 7 days will Prevent loss of lean muscle mass by within 7 days of recruitment to the study. Decrease pro-inflammatory and increase anti-inflammatory cytokines within 7 days of recruitment to the study.

Admitted to intensive care and likely to remain ventilated for > 48 hours

Exclusion Criteria:

Patients with septic shock unresponsive to maximal treatment or who are moribund or have an expected mortality within 48 hours

Head injuries

Burn injury

Multiple lower limb fractures

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01364909